

# VAS2870

**Catalog No: tcsc0012525**



## Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



## Specifications

---

**CAS No:**

722456-31-7

**Formula:**

$C_{18}H_{12}N_6OS$

**Pathway:**

Others

**Target:**

Others

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 83.3 mg/mL (231.14 mM; Need ultrasonic)

**Observed Molecular Weight:**


360.39

## Product Description

VAS2870 is a **NADPH oxidase (NOX)** inhibitor.

IC50 & Target: Target: NADPH oxidase<sup>[1]</sup>

**In Vitro:** VAS2870 is effective to suppress PDGF-BB-dependent activation of NADPH oxidase and subsequent production of intracellular ROS. Furthermore, VAS2870 suppresses PDGF-BB-dependent chemotaxis, but not DNA synthesis. Preincubation with VAS2870 (10 and 20  $\mu$ M) completely abolishes PDGF-mediated NADPH oxidase activation and ROS production. Preincubation with VAS2870 (0.1-20  $\mu$ M) does not affect PDGF-induced cell cycle progression. However, it abolishes PDGF-dependent chemotaxis of VSMC in a concentration-dependent manner (100% inhibition at 10  $\mu$ M)<sup>[1]</sup>. VAS2870 inhibits dose-dependently autocrine increase of cell number in FaO rat hepatoma cells, and almost completely blocked ROS production and thymidine incorporation when used at 25 mM. VAS2870 blocks serum-dependent cell growth of FaO rat hepatoma cells. VAS2870 inhibits proliferation of different human hepatocellular carcinoma (HCC) cell lines. VAS2870 pretreatment enhances TGF- $\beta$ -mediated apoptosis of FaO rat hepatoma cells<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!